IN THE CLAIMS:

Applicants have canceled claims 14, 17 and 18, amended claims 7, 8, 9, 10, 11 and 19 and added new claim 20. This listing of claims will replace all prior versions and listings in the application:

Claims 1 to 6 (Canceled).

- 7. (Currently Amended) A vaccine for the protection of animals against Salmonellosis, comprising an immunologically effective amount of a mutated bacterium and a pharmaceutically acceptable carrier, said mutated bacterium being selected from the group consisting of the Salmonella species typhimurium, enteritidis, choleraesuis, dublin, abortus-ovi, abortus-equi, derby, hadar, heidelberg, agona, and arizonae, that in its wild type form carries flagella, said mutated bacterium lacking flagellin.
- 8. (Currently Amended) The vaccine according to claim 7, wherein the bacteria is in a live attenuated form.
- 9. (Currently Amended) The vaccine according to claim 7, wherein the bacteria are inactivated.
 - 10. (Currently Amended) The vaccine according to claim 7, comprising an adjuvant.
- 11. (Currently Amended) The vaccine according to claim 7, in a freeze-dried or spray-dried form.

Claims 12 to 18 (Canceled).

19. (Currently Amended) A vaccine for the protection of animals against Salmonellosis,

comprising an immunologically effective amount of a mutated bacterium and a pharmaceutically acceptable carrier said mutated bacterium being selected from the group consisting of the Salmonella species typhimurium, enteritidis, choleraesuis, dublin, abortus-ovi, abortus-equi, derby, hadar, heidelberg, agona, and arizonae, that in its wild type form carries flagella, said mutated bacterium lacking at least one antigenic determinant of flagellin or flagella found in its wild type form, and said mutated bacterium being inactivated.

- 20. (New) A vaccine for the protection of animals against Salmonellosis strains, comprising:
- an immunologically effective amount of a mutated Salmonella typhimurium bacterium that in its wild type form carries flagella, said mutated Salmonella typhimurium bacterium lacking flagellin, and
- a pharmaceutically acceptable carrier.
- 21. (New) The vaccine of claim 20, wherein the immunologically effective amount of a mutated *Salmonella typhimurium* bacterium that in its wild type form carries flagella, said mutated *Salmonella typhimurium* bacterium lacking flagellin, comprises an immunologically effective amount of a *Salmonella typhimurium* STMP mutated bacterium.